Patents by Inventor Lianshan Zhang

Lianshan Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7582608
    Abstract: The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes.
    Type: Grant
    Filed: October 24, 2006
    Date of Patent: September 1, 2009
    Assignee: Eli Lilly and Company
    Inventors: Bengt Krister Bokvist, Lianshan Zhang, Jorge Alsina-Fernandez
  • Publication number: 20090215981
    Abstract: The invention provides GLP-1 compounds coupled to two polyethylene glycol molecule or derivative thereof, resulting in a biologically active peptide with an extended half-life and a slower clearance when compared to that of unPEGylated peptide. These PEGylated GLP-1 compounds and compositions are useful in treating conditions or disorders benefited by lowering blood glucose, decreasing food intake, decreasing gastric or intestinal emptying, increasing beta (?) cell population, or decreasing gastric or intestinal motility.
    Type: Application
    Filed: May 11, 2006
    Publication date: August 27, 2009
    Inventors: Wolfgang Glaesner, John Philip Mayer, Rohn Lee Millican, JR., Andrew Mark Vick, Lianshan Zhang
  • Patent number: 7557183
    Abstract: The invention provides GLP-1 compounds coupled to at least one polyethylene glycol molecule or derivative thereof, resulting in a biologically active peptide with an extended half-life and a slower clearance when compared to that of unPEGylated peptide. These PEGylated GLP-1 compounds and compositions are useful in treating diabetes, obesity, irritable bowel syndrome and other conditions that would be benefited by lowering plasma glucose, inhibiting gastric and/or intestinal motility and inhibiting gastric and/or intestinal emptying, or inhibiting food intake.
    Type: Grant
    Filed: March 19, 2004
    Date of Patent: July 7, 2009
    Assignee: Eli Lilly and Company
    Inventors: Richard Dennis DiMarchi, Wolfgang Glaesner, Rohn Lee Millican, Jr., Andrew Mark Vick, Lianshan Zhang
  • Publication number: 20090118167
    Abstract: The invention provides VPAC2R peptide agonists coupled to at least one polyethylene glycol molecule or derivative thereof, resulting in a biologically active peptide with an extended half-life and a slower clearance when compared to that of unPEGylated peptide.
    Type: Application
    Filed: August 11, 2005
    Publication date: May 7, 2009
    Applicant: Eli Lilly and Company Patent Division
    Inventors: Bengt Krister Bokvist, John Philip Mayer, Lianshan Zhang, Jorge Alsina-Fernandez, Andrew Mark Vick
  • Publication number: 20090082276
    Abstract: The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes.
    Type: Application
    Filed: February 20, 2007
    Publication date: March 26, 2009
    Inventors: Lianshan Zhang, Jorge Alsina-Fernandez
  • Patent number: 7482321
    Abstract: The invention encompasses GLP-1 peptides with modifications at various positions coupled with an extended C-terminus that provides increased stability.
    Type: Grant
    Filed: January 3, 2003
    Date of Patent: January 27, 2009
    Assignee: Eli Lilly and Company
    Inventors: Wolfgang Glaesner, Wayne David Kohn, Rohn Lee Millican, Lianshan Zhang
  • Publication number: 20080318845
    Abstract: The present invention relates to peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes.
    Type: Application
    Filed: August 11, 2005
    Publication date: December 25, 2008
    Applicant: ELI LILLY AND COMPANY
    Inventors: Bengt Krister Bokvist, Lianshan Zhang, Jorge Alsina-Fernandez
  • Publication number: 20080234198
    Abstract: The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes.
    Type: Application
    Filed: October 24, 2006
    Publication date: September 25, 2008
    Inventors: Bengt Krister Bokvist, Lianshan Zhang, Jorge Alsina-Fernandez
  • Publication number: 20080194482
    Abstract: The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes.
    Type: Application
    Filed: July 28, 2006
    Publication date: August 14, 2008
    Inventors: Jorge Alsina-Fernandez, Bengt Krister Bokvist, Lianshan Zhang
  • Publication number: 20080146500
    Abstract: The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes.
    Type: Application
    Filed: August 11, 2005
    Publication date: June 19, 2008
    Inventors: Bengt Krister Bokvist, John Philip Mayer, Lianshan Zhang, Jorge Alsina-Fernandez, Andrew Mark Vick
  • Publication number: 20080113905
    Abstract: The invention provides GLP-1 compounds coupled to at least one polyethylene glycol molecule or derivative thereof, resulting in a biologically active peptide with an extended half-life and a slower clearance when compared to that of unPEGylated peptide. These PEGylated GLP-1 compounds and compositions are useful in treating diabetes, obesity, irritable bowel syndrome and other conditions that would be benefited by lowering plasma glucose, inhibiting gastric and/or intestinal motility and inhibiting gastric and/or intestinal emptying, or inhibiting food intake.
    Type: Application
    Filed: March 19, 2004
    Publication date: May 15, 2008
    Applicant: ELI LILLY AND COMPANY
    Inventors: Richard Dennis DiMarchi, Wolgang Glaesner, John Lee Millican Jr, Andrew Mark Vick, Lianshan Zhang
  • Publication number: 20080096811
    Abstract: The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes.
    Type: Application
    Filed: May 19, 2005
    Publication date: April 24, 2008
    Applicant: Eli Lilly and Company
    Inventors: Bengt Krister Bokvist, Jesper Lindgren Gromada, Robert Chadwick Cummins, Wolfgang Glaesner, John Philip Mayer, Lianshan Zhang, Jorge Alsina-Fernandez
  • Publication number: 20080085860
    Abstract: The present invention encompasses PEGylated peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes.
    Type: Application
    Filed: August 11, 2005
    Publication date: April 10, 2008
    Applicant: ELI LILLY AND COMPANY
    Inventors: Bengt Krister Bokvist, John Phillip Mayer, Lianshan Zhang, Jorge Alsina-Fernandez, Andrew Mark Vick
  • Publication number: 20080026996
    Abstract: The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes.
    Type: Application
    Filed: May 19, 2005
    Publication date: January 31, 2008
    Applicant: ELI LILLY AND COMPANY
    Inventors: Bengt Bokvist, Jesper Gromada, Robert Cummins, Wolfgang Glaesner, John Mayer, Lianshan Zhang, Jorge Alsina-Fernandez
  • Publication number: 20070105759
    Abstract: The present invention relates to peptide agonists of the MC4 receptor, and as such are useful in the treatment of disorders responsive to the activation of this receptor, such as obesity, diabetes mellitus and male and/or female sexual dysfunction.
    Type: Application
    Filed: June 17, 2004
    Publication date: May 10, 2007
    Applicant: ELI LILLY AND COMPANY
    Inventors: David Flora, Mark Heiman, JeAnne Hertel, Hansen Hsiung, John Mayer, David Smiley, Liang Yan, Lianshan Zhang
  • Publication number: 20060252916
    Abstract: The invention encompasses GLP-1 compounds containing a GLP-1 peptide or a GLP-1 peptide with an extended C-terminus that is modified with a reactive group that is capable of forming covalent bonds with a blood component to form a conjugate. The conjugates may be formed in vivo or ex vivo. Methods of treating a subject in need of GLP-1 receptor stimulation using these GLP-1 compounds are also disclosed.
    Type: Application
    Filed: June 2, 2003
    Publication date: November 9, 2006
    Applicant: ELI LILLY AND COMPANY
    Inventors: Richard DiMarchi, Lianshan Zhang
  • Publication number: 20060252693
    Abstract: Disclosed are glucagon-like peptide-1 (GLP-1) compounds with modifications at one or more of the following positions: 7, 8, 12, 16, 18, 19, 20, 22, 25, 27, 30, 33, and 37. Methods of treating a subject in need of GLP-1 receptor stimulation using these GLP-1 compounds are also disclosed.
    Type: Application
    Filed: July 6, 2006
    Publication date: November 9, 2006
    Inventors: Wolfgang Glaesner, Rohn Millican, Lianshan Zhang
  • Publication number: 20060217290
    Abstract: The present invention provides the insulin analog A0Arg A21Gly B31Arg B32Arg, which provides a protracted, even basal duration of action. The present invention also provides a method of treating diabetes mellitus comprising administering the insulin analog.
    Type: Application
    Filed: April 22, 2004
    Publication date: September 28, 2006
    Inventors: Wayne Kohn, Lianshan Zhang, Richard Dimarchi
  • Patent number: 7101843
    Abstract: Disclosed are glucagon-like peptide-1 (GLP-1) compounds with modifications at one or more of the following positions: 7, 8, 12, 16, 18, 19, 20, 22, 25, 27, 30, 33, and 37. Methods of treating a subject in need of GLP-1 receptor stimulation using these GLP-1 compounds are also disclosed.
    Type: Grant
    Filed: August 14, 2002
    Date of Patent: September 5, 2006
    Assignee: Eli Lilly and Company
    Inventors: Wolfgang Glaesner, Rohn Lee Millican, Lianshan Zhang
  • Publication number: 20060014241
    Abstract: The invention encompasses GLP-1 peptides with modifications at various positions coupled with an extended C-terminus that provides increased stability.
    Type: Application
    Filed: January 3, 2003
    Publication date: January 19, 2006
    Inventors: Wolfgang Glaesner, Wayne Kohn, Rohn Millican, Lianshan Zhang